GlaxoSmithKline Pharmaceuticals is investing Rs 1,000 crore in a new state-of-the-art pharmaceutical unit located at Vemgal in state of Karnataka and is looking at enhancing its global pipeline in areas like respiratory drugs and vaccines in India.
The factory will initially supply a range of solid dose form products. The factory will commence production in 2018 and produce more than 8 billion tablets and 1 billion capsules a year.
GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.
